Asset Details
Do you wish to reserve the book?
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Do you wish to request the book?
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
2015
Overview
The addition of elotuzumab (a monoclonal antibody against SLAMF7) to lenalidomide plus dexamethasone produced a significant increase in progression-free survival as compared with lenalidomide plus dexamethasone alone.
Multiple myeloma, a malignant disease of monoclonal plasma cells, has a median overall survival of approximately 5 years.
1
Despite improvements in treatment outcomes with proteasome inhibitors and immunomodulatory drugs, most patients continue to have a relapse, and new treatment approaches are needed. Combination therapy may be key to overcoming drug resistance and improving long-term treatment outcomes. Lenalidomide, an immunomodulatory drug, in combination with dexamethasone is a standard regimen in patients with relapsed or refractory disease.
2
,
3
Three-drug combinations are emerging for patients with previously treated multiple myeloma
3
but may be limited by toxic effects. Agents with new mechanisms of action . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Age
/ Aged
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Dexamethasone - therapeutic use
/ Fatigue
/ Humans
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - mortality
/ Receptors, Immunologic - antagonists & inhibitors
/ Signaling Lymphocytic Activation Molecule Family
/ Survival
/ Thalidomide - analogs & derivatives
